BACKGROUND: TP53I13 is a protein coding tumor suppression gene encoded by the tumor protein p53. Overexpression of impedes tumor cell proliferation. Nevertheless, role and expression in the emergence and progression of glioma (low-grade glioma and glioblastoma) are yet to be identified. Thus, we aim to use comprehensive bioinformatics analyses to investigate TP53I13 and its prognostic value in gliomas. METHODS: Multiple databases were consulted to evaluate and assess the expression of , such as the Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), GeneMANIA, and Gene Expression Profiling Interactive. expression was further explored using immunohistochemistry (IHC) and multiplex immunohistochemistry (mIHC). Through Gene Set Enrichment Analysis (GSEA), the biological functions of and metastatic processes associated with it were studied. RESULTS: The expression of was higher in tumor samples compared to normal samples. In samples retrieved from the TCGA and CGGA databases, high expression was associated with poor survival outcomes. The analysis of multivariate Cox showed that might be an independent prognostic marker of glioma. It was also found that increased expression of was significantly correlated with PRS type, status, 1p/19q codeletion status, IDH mutation status, chemotherapy, age, and tumor grade. According to CIBERSORT (Cell-type Identification by Estimating Relative Subsets of RNA Transcript), the expression of correlates with macrophages, neutrophils, and dendritic cells. GSEA shows a close correlation between and p53 signaling pathways, DNA replication, and the pentose phosphate pathway. CONCLUSION: Our results reveal a close correlation between and gliomas. Further, expression could affect the survival outcomes in glioma patients. In addition, was an independent marker that was crucial in regulating the infiltration of immune cells into tumors. As a result of these findings, might represent a new biomarker of immune infiltration and prognosis in patients with gliomas.